Factors influencing the outcome of donor marrow transplantation in adults from less than ideal donors: experience from two Australian centres.
BACKGROUND
This paper reports the results of 78 marrow transplants in two Australian hospitals between 1991 and 1996, using unrelated (n = 54) or mismatched related (n = 24) donors. Twenty-six patients received granulocyte-macrophage colony stimulating factor (GM-CSF) post-transplant as part of a phase II study. Fifty-four patients (74%) had advanced disease.


OBJECTIVE
To identify factors associated with a superior outcome post-transplant, to evaluate the effect of GM-CSF on engraftment and other transplant parameters, and to compare the overall results with those of published series.


METHODS
Review of patient records, a Medline search of the relevant literature and appropriate statistical analysis.


RESULTS
The probability of overall survival and event-free survival (EFS) at three years was 35 +/- 6% and 22 +/- 6% respectively. Pre-transplant factors significantly associated with an inferior EFS were advanced disease, poorer performance status and age > 30 years. The EFS in patients with standard risk disease was 51 +/- 13% versus 10 +/- 5% in patients with advanced disease, p < 0.0001. Severe acute graft-versus-host disease was also associated with a poorer outcome. Neutrophil engraftment was faster in patients who received GM-CSF but there was no difference in any other transplant parameters.


CONCLUSIONS
These results are consistent with reported series elsewhere and suggest that an extended family or unrelated donor transplant should generally be limited to patients with a good performance status and early phase but otherwise incurable haematological disease.
Grigg
A
A
Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Vic.
Morton
J
J
Durrant
S
S
Bardy
P
P
Szer
J
J
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007938:Leukemia / Q000601:surgery*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000601:surgery; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery; D007951:Leukemia, Myeloid / Q000601:surgery; D008297:Male; D018579:Patient Selection; D012189:Retrospective Studies; D016896:Treatment Outcome
D006680:HLA Antigens; D016178:Granulocyte-Macrophage Colony-Stimulating Factor